Edition:
United Kingdom

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

11.17USD
12 Dec 2017
Change (% chg)

$-0.23 (-2.02%)
Prev Close
$11.40
Open
$11.45
Day's High
$11.70
Day's Low
$11.08
Volume
80,290
Avg. Vol
219,840
52-wk High
$25.95
52-wk Low
$5.42

Chart for

About

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which... (more)

Overall

Beta: --
Market Cap(Mil.): $128.07
Shares Outstanding(Mil.): 13.26
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Zynerba Pharmaceuticals reports Q3 loss per share of $0.63

* Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights

14 Nov 2017

Zynerba's stock on a high as cannabis-based drug succeeds in trial

Zynerba Pharmaceuticals Inc said on Thursday its cannabis-derived gel to treat genetic disorder Fragile X syndrome succeeded in significantly reducing symptoms such as anxiety in a mid-stage study.

28 Sep 2017

UPDATE 3-Zynerba's stock on a high as cannabis-based drug succeeds in trial

* Shares rise nearly 60 percent (Adds details on company's plans, analyst comment, updates share price)

28 Sep 2017

BRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study

* Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study in children with Fragile X syndrome

28 Sep 2017

Zynerba's cannabis-based gel succeeds in mid-stage study

Sept 28 Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel succeeded in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities.

28 Sep 2017

BRIEF-Zynerba Pharmaceuticals announces results from phase 2 STOP clinical trial

* Zynerba Pharmaceuticals announces that results from phase 2 stop trial support continued development of ZYN002 in osteoarthritis

14 Aug 2017

Zynerba shares plunge as cannabis-based epilepsy gel fails study

Zynerba Pharmaceuticals Inc's stock lost more than half its value on Monday after the U.S. drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage study.

07 Aug 2017

UPDATE 2-Zynerba shares plunge as cannabis-based epilepsy gel fails study

* ZYNE stock sinks about 60 pct, GW shares rise 4 pct (Adds analysts' comments, conf. call details, GW shares; updates ZYNE shares)

07 Aug 2017

Zynerba's cannabis-based gel for epilepsy fails study

Aug 7 Zynerba Pharmaceuticals said on Monday its experimental synthetic cannabis-based gel failed to induce a statistically significant reduction in seizures in a mid-stage study involving epilepsy patients.

07 Aug 2017

BRIEF-Zynerba Pharma announces top-line results from phase 2 star 1 trial of ZYN002

* Zynerba Pharmaceuticals announces top-line results from phase 2 star 1 trial of ZYN002 in adult epilepsy patients with focal seizures

07 Aug 2017

Earnings vs. Estimates